What are the CDC guidelines on dolutegravir for the treatment of HIV infection in women?

Updated: Jan 15, 2019
  • Author: Jason F Okulicz, MD, FACP, FIDSA; more...
  • Print
Answer

Answer

Preliminary data have raised concerns about an increased risk of neural tube defects in infants born to patients who were receiving dolutegravir at the time of conception. Healthcare providers who are prescribing postexposure prophylaxis (PEP) should avoid dolutegravir in the following female patient groups:

  • Nonpregnant women of childbearing potential who are sexually active or have been sexually assaulted and who are not using an effective birth control method
  • Pregnant women early in pregnancy, since the risk of an unborn infant developing a neural tube defect is during the first 28 days of pregnancy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!